NEW YORK, Sept. 15, 2022 (GLOBE NEWSWIRE) — Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that the United States District Court for the District of Connecticut on behalf of investors who own Sema4 Holdings Corp. (“Sema4” or the “Company”) purchased or acquired a federal securities class action lawsuit has been filed. SMFR between March 14, 2022 and August 15, 2022 inclusive (the “Collection Period”).

All investors who own the shares of Sema4 Holdings Corp. and any losses incurred are advised to contact the company immediately at [email protected] or (800) 575-0735 or (212) 545-4774. You can get additional information about the promotion or join the case on our website, www.whafh.com.

When you join Sema4 Holdings Corp. Have suffered losses, you can at the latest November 7, 2022, request that the court appoint you lead plaintiff in the proposed class. Please contact Wolf Haldenstein to learn more about your rights as an investor in Sema4 Holdings Corp. to experience.

PLEASE CLICK HERE TO JOIN THE EVENT

Sema4 is a healthcare company that uses artificial intelligence to enable personalized medicine. The company’s platform leverages longitudinal patient data, AI-powered predictive modeling and genomics in combination with other data to deliver better outcomes for patients. Sema4 derives the majority of its sales from diagnostic solutions in women’s health and oncology.

The lawsuit alleges that the defendants made materially false and misleading statements throughout the class action period. Specifically, Plaintiff alleges that Defendants failed to disclose:

• that there was a significant risk that Sema4 would reverse a significant amount of previously recognized revenue that it was unable to recover from third-party payers;

• that the company experienced decreasing selling prices for its reproductive health segment; and

• that as a result of the foregoing, Sema4’s financial results would be adversely affected.
  

On August 15, 2022, after market close, Sema4 announced…